High lung deposition of 99mTc-labelled ciclesonide administered via HFA-MDI to asthma patients

S. Newman, A. Salmon, R. Nave, A. Drollmann (Ruddington, United Kingdom; Konstanz, Germany)

Source: Annual Congress 2004 - Improvements in delivery of inhaled agents
Session: Improvements in delivery of inhaled agents
Session type: Thematic Poster Session
Number: 3581
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Newman, A. Salmon, R. Nave, A. Drollmann (Ruddington, United Kingdom; Konstanz, Germany). High lung deposition of 99mTc-labelled ciclesonide administered via HFA-MDI to asthma patients. Eur Respir J 2004; 24: Suppl. 48, 3581

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetics of tiotropium administered by Respimat in adolescent asthma patients
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017


Lung deposition of fluticasone propionate/formoterol administered via a breath-triggered inhaler
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

High dose inhaler corticosteroids in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004

Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Lung deposition of BDP/formoterol HFA pMDI in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2008 - Imaging of different lung diseases: clinical and experimental observations
Year: 2008


High doses of inhaled formoterol have less systemic effect in asthmatic children than high doses of inhaled terbutaline
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001

Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 100s
Year: 2007

Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001

Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo
Source: Eur Respir J 2004; 24: Suppl. 48, 345s
Year: 2004

Cardiovascular effects of a high dose of the budesonide/formoterol single inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 54s
Year: 2001

High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 125s
Year: 2005

The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 43s
Year: 2001

Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction
Source: Eur Respir J 2001; 18: 928-934
Year: 2001